Skip to main content
. 2020 Jan 17;12(1):230. doi: 10.3390/cancers12010230

Figure 2.

Figure 2

Correlation of tumor mutational burden (TMB) determined by real-life WES and targeted gene panels: real-life WES vs. in silico MSK-IMPACT (A), in silico F1CDx vs. MSK-IMPACT (B), real-life WES vs. in silico F1CDx (C), real-life WES vs. real-life laboratory service F1Heme (D).